-
21.发明授权公开(公告)号：US06495552B2
公开(公告)日：2002-12-17
申请号：US09963318
申请日：2001-06-07
IPC分类号： A61K31495
CPC分类号： C07D221/20 , A61K31/192 , A61K31/195 , A61K31/353 , A61K31/382 , A61K31/47 , A61K31/472 , A61K31/4747 , C07C59/72 , C07C65/28 , C07D215/14 , C07D217/04 , C07D231/12 , C07D233/56 , C07D249/08 , C07D311/70 , C07D311/96 , C07D333/40 , C07D335/04 , C07D335/06 , C07D409/06
摘要： Novel compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification, and certain previously known compounds have been discovered to act as inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. The compound can also be used in co-treatment with retinoids.
-
公开(公告)号：US06399774B1
公开(公告)日：2002-06-04
申请号：US09829097
申请日：2001-04-09
IPC分类号： C07D23702
CPC分类号： C07D221/20 , A61K31/192 , A61K31/195 , A61K31/353 , A61K31/382 , A61K31/47 , A61K31/472 , A61K31/4747 , C07C59/72 , C07C65/28 , C07D215/14 , C07D217/04 , C07D231/12 , C07D233/56 , C07D249/08 , C07D311/96 , C07D333/40 , C07D335/04 , C07D335/06 , C07D409/06
摘要： Compounds having Formula 1 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.
摘要翻译： 具有式1的化合物，其中符号具有本说明书中定义的含义是细胞色素P450RAI（视黄酸诱导型）酶的抑制剂，并且用于治疗响应于类视黄醇治疗的疾病。
-
公开(公告)号：US06387951B1
公开(公告)日：2002-05-14
申请号：US09651234
申请日：2000-08-29
IPC分类号： A61K31192
摘要： Compounds having Formulas 5 and 6 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.
-
24.发明授权Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI 失效提供和使用具有活性的化合物作为细胞色素P450RAI抑制剂的方法公开(公告)号：US06387892B1
公开(公告)日：2002-05-14
申请号：US09875967
申请日：2001-06-07
IPC分类号： A61K31655
CPC分类号： C07D221/20 , A61K31/192 , A61K31/195 , A61K31/353 , A61K31/382 , A61K31/47 , A61K31/472 , A61K31/4747 , C07C59/72 , C07C65/28 , C07D215/14 , C07D217/04 , C07D231/12 , C07D233/56 , C07D249/08 , C07D311/70 , C07D311/96 , C07D333/40 , C07D335/04 , C07D335/06 , C07D409/06
摘要： Novel compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification, and certain previously known compounds have been discovered to act as inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. The compound can also be used in co-treatment with retinoids.
摘要翻译： 具有式1至8的新化合物，其中符号具有说明书中定义的含义，并且已经发现某些先前已知的化合物作为细胞色素P450RAI（视黄酸诱导型）酶的抑制剂，并用于治疗疾病反应性 由维甲酸治疗。 该化合物也可用于与类维生素A的共处理。
-
25.发明授权Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI 失效提供和使用具有活性的化合物作为细胞色素P450RAI抑制剂的方法公开(公告)号：US06313107B1
公开(公告)日：2001-11-06
申请号：US09672751
申请日：2000-09-28
IPC分类号： A61K31655
CPC分类号： C07D221/20 , A61K31/192 , A61K31/195 , A61K31/353 , A61K31/382 , A61K31/47 , A61K31/472 , A61K31/4747 , C07C59/72 , C07C65/28 , C07D215/14 , C07D217/04 , C07D231/12 , C07D233/56 , C07D249/08 , C07D311/70 , C07D311/96 , C07D333/40 , C07D335/04 , C07D335/06 , C07D409/06
摘要： Novel compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification, and certain previously known compounds have been discovered to act as inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. The compound can also be used in co-treatment with retinoids.
摘要翻译： 具有式1至8的新化合物，其中符号具有说明书中定义的含义，并且已经发现某些先前已知的化合物作为细胞色素P450RAI（视黄酸诱导型）酶的抑制剂，并用于治疗疾病反应性 由维甲酸治疗。 该化合物也可用于与类维生素A的共处理。
-
26.发明申请Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same 失效具有选择性细胞色素P450RAI-1或选择性细胞色素P450RAI-2抑制活性的化合物及其获得方法公开(公告)号：US20080004455A1
公开(公告)日：2008-01-03
申请号：US11728313
申请日：2007-03-23
申请人： Jayasree Vasudevan , Liming Wang , Xiaoxia Liu , Kwok Tsang , Ling Li , Janet Takeuchi , Thong Vu , Richard Beard , Smita Bhat , Vidyasagar Vuligonda , Roshantha Chandraratna
发明人： Jayasree Vasudevan , Liming Wang , Xiaoxia Liu , Kwok Tsang , Ling Li , Janet Takeuchi , Thong Vu , Richard Beard , Smita Bhat , Vidyasagar Vuligonda , Roshantha Chandraratna
IPC分类号： C07D311/96 , C07C229/44 , C07C63/331 , C07D311/04
CPC分类号： C07C69/73 , C07C57/42 , C07C59/64 , C07C59/86 , C07C69/753 , C07C69/76 , C07C229/34 , C07C229/38 , C07C229/46 , C07C229/50 , C07C275/42 , C07C2601/02 , C07C2602/10 , C07D311/58 , C07D311/64 , C07D311/96
摘要： Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
摘要翻译： 在说明书中提供的式1至17的化合物具体地或选择性地抑制细胞色素P450RAI-1酶或细胞色素P450RAI-2酶。
-
27.发明申请Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same 失效具有选择性细胞色素P450RAI-1或选择性细胞色素P450RAI-2抑制活性的化合物及其获得方法公开(公告)号：US20050176689A1
公开(公告)日：2005-08-11
申请号：US11014460
申请日：2004-12-16
申请人： Jayasree Vasudevan , Liming Wang , Xiaoxia Liu , Kwok Tsang , Ling Li , Janet Takeuchi , Thong Vu , Richard Beard , Smita Bhat , Vidyasagar Vuligonda , Roshantha Chandraratna
发明人： Jayasree Vasudevan , Liming Wang , Xiaoxia Liu , Kwok Tsang , Ling Li , Janet Takeuchi , Thong Vu , Richard Beard , Smita Bhat , Vidyasagar Vuligonda , Roshantha Chandraratna
IPC分类号： C07C57/42 , C07C59/64 , C07C59/86 , C07C69/18 , C07C69/73 , C07C69/753 , C07C69/76 , C07C229/34 , C07C229/38 , C07C229/46 , C07C229/50 , C07C275/42 , C07D311/58 , C07D311/64 , C07D311/96 , A61K31/655 , A61K31/4747 , A61K31/497 , A61K31/502 , A61K31/506
CPC分类号： C07C69/73 , C07C57/42 , C07C59/64 , C07C59/86 , C07C69/753 , C07C69/76 , C07C229/34 , C07C229/38 , C07C229/46 , C07C229/50 , C07C275/42 , C07C2601/02 , C07C2602/10 , C07D311/58 , C07D311/64 , C07D311/96
摘要： Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
摘要翻译： 在说明书中提供的式1至17的化合物具体地或选择性地抑制细胞色素P450RAI-1酶或细胞色素P450RAI-2酶。
-
28.发明授权Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors 失效对类视黄醇X（RXR）受体具有选择性活性的二氢苯并呋喃和二氢苯并噻吩2,4-戊二烯酸衍生物公开(公告)号：US06720423B2
公开(公告)日：2004-04-13
申请号：US10135595
申请日：2002-04-30
IPC分类号： A61K3134
CPC分类号： C07D307/79
摘要： Compounds of the formula where the variables have the meaning defined in the specification, are specific or selective agonists of RXR retinoid receptors.
摘要翻译： 变体具有本说明书中定义的含义的化合物是RXR类视黄醇受体的特异性或选择性激动剂。
-
29.发明授权3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity 失效具有血清葡萄糖降低活性的3,5-二异丙基 - 七三烯酸衍生物公开(公告)号：US06759546B1
公开(公告)日：2004-07-06
申请号：US10357911
申请日：2003-02-04
IPC分类号： C07C6976
CPC分类号： C07C59/68 , C07C69/734
摘要： Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effect of reducing serum thyroxine levels.
摘要翻译： 所述变体具有本说明书中定义的含义的化合物能够降低糖尿病哺乳动物的血清葡萄糖水平，而没有降低血清甲状腺素水平的不良副作用。
-
30.发明申请Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B 失效使用CYP26A和CYP26B的选择性抑制剂治疗类视黄醇应答障碍的方法公开(公告)号：US20050187298A1
公开(公告)日：2005-08-25
申请号：US11010953
申请日：2004-12-13
申请人： Jayasree Vasudevan , Rong Yang , Liming Wang , Xiaoxia Liu , Kwok-Yin Tsang , Ling Li , Janet Takeuchi , Thong Vu , Richard Beard , Smita Bhat , Roshantha Chandraratna
发明人： Jayasree Vasudevan , Rong Yang , Liming Wang , Xiaoxia Liu , Kwok-Yin Tsang , Ling Li , Janet Takeuchi , Thong Vu , Richard Beard , Smita Bhat , Roshantha Chandraratna
IPC分类号： A61K31/19 , A61K31/192 , A61K31/35 , A61K31/38
CPC分类号： A61K31/19 , A61K31/192 , A61K31/35 , A61K31/38
摘要： The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.
摘要翻译： 本发明提供了治疗患有类视黄醇反应性障碍的个体的方法。 在一个实施方案中，一种方法涉及向个体施用有效量的选择性CYP26B抑制剂，所述选择性CYP26B抑制剂相对于CYP26A对CYP26B具有至少10倍的选择性。 在另一个实施方案中，一种方法包括向个体施用有效量的选择性CYP26A抑制剂，该选择性CYP26A抑制剂具有说明书中阐述的化学式。 本发明还提供用于鉴定选择性CYP26A抑制剂或选择性CYP26B抑制剂的筛选方法。
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.056 秒)
